Delonix Bioworks
Startup
Delonix Bioworks is a leading biotech dedicated to developing next-generation genetically engineered bacterial vaccines. Founded in 2021, we raised $14M seed funding led by Boehringer Ingelheim Venture Fund and IDG, with the mission to transform bacterial vaccine development from empirical approaches to rational design. Delonix has developed comprehensive genome editing toolkits for over 15 pathogens and established multiple proprietary vaccine technology platforms, particularly the next-generation engineered Outer Membrane Vesicle (OMV) technology platform– OMV Plus. Our flagship OMV Plus platform is a state-of-the-art technology that produces OMV vaccine candidates with enhanced efficacy and safety profiles. It enables scalable, cost-effective production and significantly accelerates the development timeline.
We welcome licensing-out opportunities for multiple pipelines and co-development opportunities based on our proprietary OMV Plus platform. Licensing-out opportunities include MenB OMV vaccine, gonorrhea OMV vaccine, pertussis OMV vaccine, Klebsiella OMV vaccine, and genetically live attenuated SA vaccine. Our lead program, a Meningococcal Group B vaccine candidate, shows best-in-class profiles and is currently pursuing IND submission in China and Australia. Other candidates have promising preclinical proof-of-concept data and are ready for further discussion.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events